Vistagen Therapeutics Appoints New CFO and Discloses Executive Compensation Arrangements
Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, reporting appointment of new CFO and related compensatory arrangements under Item 5.02.
51CFO view：Item 5.02 filings require immediate SOX 302 certifications and full disclosure of employment agreements. For pre-IPO companies, this underscores that CFO candidates must have verifiable SEC signing authority history and documented experience leading ≥2 annual 10-K cycles.
Vistagen Therapeutics, Inc. (SEC file no. 0001411685) filed an 8-K on October 9, 2026, reporting appointment of new CFO and related compensatory arrangements under Item 5.02.
Source：SEC EDGAR · 8-K 重大事项公告